H.R. 3358 - Departments of Labor, Health and Human Services, and Related Agencies Appropriations Act, 2018
S. 1771 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2018
H.R. 1625, Consolidated Appropriations Act for fiscal year 2018
H.R. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
S. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
H.R. unnumbered, Defense Appropriations Act for fiscal year 2019
S. unnumbered, Defense Appropriations Act for fiscal year 2019
H.R. unnumbered, National Defense Authorization Act for fiscal year 2019, defense medical research
S. unnumbered, National Defense Authorization Act for fiscal year, 2019 defense medical research
Duration: July 10, 2006
to
March 31, 2018
General Issues: Budget/Appropriations , Defense , Health Issues , Medicare/Medicaid , Medical/Disease Research/Clinical Labs , Taxation/Internal Revenue Code , Science/Technology
Spending: about $3,301,557 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2006: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), President of the U.S., Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Social Security Administration (SSA), Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Labor - Dept of (DOL), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2018
PANCREATIC CANCER ACTION NETWORK (PANCAN) in-house lobbying effort was terminated on July 12, 2018
Original Filing: 300964353.xml
Lobbying Issues
H.R. 3358 - Departments of Labor, Health and Human Services, and Related Agencies Appropriations Act, 2018
S. 1771 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2018
H.R. 1625, Consolidated Appropriations Act for fiscal year 2018
H.R. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
S. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
H.R. unnumbered, Defense Appropriations Act for fiscal year 2019
S. unnumbered, Defense Appropriations Act for fiscal year 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. unnumbered, National Defense Authorization Act for fiscal year 2019, defense medical research
S. unnumbered, National Defense Authorization Act for fiscal year, 2019 defense medical research
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 19, 2018.
Original Filing: 300951801.xml
Lobbying Issues
H.R. 3358 - Departments of Labor, Health and Human Services, and Related Agencies Appropriations Act, 2018
S. 1771 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2018
H.R. 1625, Consolidated Appropriations Act for fiscal year 2018
H.R. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
S. unnumbered, Labor-Health and Human Services Act for fiscal year 2019
H.R. unnumbered, Defense Appropriations Act for fiscal year 2019
S. unnumbered, Defense Appropriations Act for fiscal year 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. unnumbered, National Defense Authorization Act for fiscal year 2019, defense medical research
S. unnumbered, National Defense Authorization Act for fiscal year, 2019 defense medical research
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300928187.xml
Lobbying Issues
H.R. 3358 - Departments of Labor, Health and Human Services, and Related Agencies Appropriations Act, 2018
S. 1771 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2018
Omnibus appropriations Senate & House
Agencies Lobbied
U.S. Senate
Lobbying Issues
Bipartisan Health Care Stabilization Act of 2017 (Alexander-Murray legislation)
Lobbying Issues
H.R. 2810 - FY18 National Defense Authorization Act (NDAA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 19, 2017.
Original Filing: 300908036.xml
Lobbying Issues
H.R. 3358 - Departments of Labor, Health and Human Services, and Related Agencies Appropriations Act, 2018
S. 1771 - Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 1628 - American Health Care Act (Senate substitute); opposing provisions related to pre-existing conditions
Graham-Cassidy substitute to AHCA
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 1519 - FY18 National Defense Authorization Act (NDAA); Support for Durbin-Blunt amendment negating sections 733, 891, 892 and 893
H.R. 2810 - FY18 National Defense Authorization Act (NDAA)
2nd Quarter, 2017
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 21, 2017.
Original Filing: 300897830.xml
Lobbying Issues
FY17 Labor, Health & Human Services & Education Appropriations Bill - NIH and NCI funding provisions
FY18 Labor, Health & Human Services & Education Appropriations Bill - NIH and NCI funding provisions
FY17 Department of Defense Appropriations bill - Congressionally Directed Medical Research Program funding and Peer-Reviewed Cancer Research Program funding
FY18 Department of Defense Appropriations bill - Congressionally Directed Medical Research Program funding and Peer-Reviewed Cancer Research Program funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act of 2017
FDA Reauthorization Act of 2017 - provisions related to the reauthorization of the user fee amendments
Better Health Care Act - June 22 version - provisions related to essential health benefits and pre-existing conditions
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 18, 2017.
Original Filing: 300868290.xml
Lobbying Issues
FY17 Labor, Health & Human Services & Education Appropriations Bill - NIH and NCI funding provisions
FY18 Labor, Health & Human Services & Education Appropriations Bill - NIH and NCI funding provisions
FY17 Department of Defense Appropriations bill - Congressionally Directed Medical Research Program funding and Peer-Reviewed Cancer Research Program funding
FY18 Department of Defense Appropriations bill - Congressionally Directed Medical Research Program funding and Peer-Reviewed Cancer Research Program funding
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Health Care Act of 2017
Supporting the use of plain language summaries of clinical trials results
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 20, 2017.
Original Filing: 300852243.xml
Lobbying Issues
Funding for cancer research in the FY17 Labor, Health & Human Services and Education Appropriations bill
Funding for pancreatic cancer research in the FY17 Department of Defense Appropriations bill
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support for the NIH and cancer research funding provisions of the 21st Century Cures Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 13, 2016.
Original Filing: 300827634.xml
Lobbying Issues
Funding for cancer research in the FY17 Labor, Health & Human Services and Education Appropriations bill
Funding for pancreatic cancer research in the FY17 Department of Defense Appropriations bill
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 20, 2016.
Original Filing: 300821756.xml
Lobbying Issues
Funding for cancer research in the FY17 Labor, Health & Human Services and Education Appropriations bill
Support for H.Res. 717 and S.Res. 459, which designate May as National Cancer Research Month
Funding for pancreatic cancer research in the FY17 Department of Defense Appropriations bill
Agencies Lobbied
U.S. Senate
Lobbying Issues
Concerns with the proposed Medicare Part B demonstration project
Agencies Lobbied
U.S. Senate
Lobbying Issues
Opposed Sections 756 and 898 of S.2943, the 2017 National Defense Authorization Act, which would prohibit funding for medical research at the Department of Defense (DoD) unless such research meets certain narrowly defined criteria related to military relevance
1st Quarter, 2016
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300799054.xml
Lobbying Issues
Funding for cancer research in the FY17 Labor, Health & Human Services and Education Appropriations bill
Funding for pancreatic cancer research in the FY17 Department of Defense Appropriations bill
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting the January 2016 revisions to the Common Rule
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Supporting requiring that CMS develop quality measures that focus on the health outcomes of those with chronic diseases where cancer is considered a chronic condition
4th Quarter, 2015
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 20, 2016.
Original Filing: 300779917.xml
Lobbying Issues
Funding for cancer research in the FY16 Labor, Health & Human Services and Education Appropriations bill and in the Omnibus bill
Support for the provisions in the 21st Century Cures Act (HR 6) that would increase funding for the National Institutes of Health
Agencies Lobbied
U.S. Senate
Lobbying Issues
Recommending that CMS adopt an Alternative Payment System that would ensure the delivery of high-quality survivorship care to Medicare beneficiaries who are cancer survivors.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 19, 2015.
Original Filing: 300758804.xml
Lobbying Issues
Funding for cancer research in the FY16 Labor, Health & Human Services and Education Appropriations bill
Support for the provisions in the 21st Century Cures Act (HR 6) that would increase funding for the National Institutes of Health
Agencies Lobbied
U.S. Senate
Lobbying Issues
Requesting that the NIH broaden its definition of "disease burden" to include diseases with very low five-year survival rates as part of the NIH-wide strategic plan.
Agencies Lobbied
Natl Institutes of Health (NIH)
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300745462.xml
Lobbying Issues
Funding for cancer research in the FY16 Labor, Health & Human Services and Education Appropriations bill
Opposition to Amendment #1482 to the FY2015 National Defense Authorization Act that prohibits funding for much of the medical research currently funded under the Department of Defense's Peer Reviewed Cancer Research Program
Support for the provisions in the 21st Century Cures Act (HR 6) that would increase funding for the National Institutes of Health
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting the NIH's Precision Medicine cohort and requesting that the NIH use it as a tool in the development of early detection tools for our nation's deadliest cancers;
Supporting the use of predictive biomarkers and asking the FDA to develop a strategy to accelerate the approval of targeted therapies for the deadliest cancers
Agencies Lobbied
Natl Institutes of Health (NIH)
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300724726.xml
Lobbying Issues
Funding for cancer research in the FY16 Labor, Health & Human Services and Education Appropriations bill
Funding for the Department of Defense's Peer Reviewed Cancer Research Program and requesting that pancreatic cancer once again be included as an eligible disease in the program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Supporting the FDA's framework for Laboratory Developed Tests (LDTs) and noting the importance of considering gene panels
Commending NIH for advancing an IRB policy that encourages efficiency while protecting those that participate in research
Supporting the American Cures Act
Outlining priorities for the 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300704232.xml
Lobbying Issues
Funding for cancer research in the FY 2015 Labor, Health & Human Services Appropriations Bill, the FY 2015 Department of Defense Appropriations Bill, and the Consolidated and Further Continuing Appropriations Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Requesting that the FDA include pancreatic cancer as one of the FDA-designated disease areas for patient-focused drug development meetings in FY 2016-2017.
Supporting patient participation in FDA medical product reviews.
Agencies Lobbied
Food & Drug Administration (FDA)
3rd Quarter, 2014
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300688005.xml
Lobbying Issues
Funding for cancer research in the FY 2015 Labor, Health & Human Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 21, 2014.
Original Filing: 300668278.xml
Lobbying Issues
Funding for cancer research in the FY 2015 Labor, Health & Human Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 21, 2014.
Original Filing: 300648381.xml
Lobbying Issues
Funding for cancer research in the FY 2015 Labor, Health & Human Services Appropriations Bill
Support for the American Cures Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support of FDA proposed rule on Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products
Support of change in SSA compassionate allowances listing on pancreatic ductal adenocarcinoma
Support of CMS' steps to address various issues in the federally facilitated marketplace
Agencies Lobbied
Food & Drug Administration (FDA)
Lobbying Issues
Opposing CMS' proposal to remove three classes of drugs from the "protected classes" status in Medicare Part D
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2013
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 17, 2014.
Original Filing: 300617822.xml
Lobbying Issues
Funding for cancer research in the FY 2014 Labor, Health & Human Services Appropriations Bill and Omnibus bill
FDA user fees
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Maintaining Orhpan Drug Tax Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 21, 2013.
Original Filing: 300604062.xml
Lobbying Issues
Funding for cancer research in the FY 2014 Labor, Health & Human Services Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Support of the compassionate allowances program within the Social Security Administration
FDA draft guidance on expedited programs for serious conditions
Drug compounding and drug supply chain security
Agencies Lobbied
Social Security Administration (SSA)
Lobbying Issues
Support of Orphan Drug tax credits
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 19, 2013.
Original Filing: 300579284.xml
Lobbying Issues
Funding for medical and cancer research in the FY 2014 Labor, Health, & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of the Affordable Care Act: plans with multiple out-of-pocket limits do not have separate caps that exceed the total overall out-of-pocket limit established by the Act and urging guidance on implementation of the clinical trials provisions
Comments to FDA on Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making
Protection of the drug supply chain systemSupport for amending the Federal Food, Drug, and Cosmetic Act to revise the pharmaceutical distribution supply chain (H.R. 1919) to promote traceability
Agencies Lobbied
Defense - Dept of (DOD)
1st Quarter, 2013
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 22, 2013.
Original Filing: 300564563.xml
Lobbying Issues
Funding for cancer research in the FY 2013 Labor, Health, & Human Services Appropriations bill
Funding for cancer research in the FY 2014 Labor, Health, & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma
Drug Shortages
Agencies Lobbied
Health & Human Services - Dept of (HHS)
4th Quarter, 2012
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300541374.xml
Lobbying Issues
Funding for cancer research in the FY 2013 Labor, Health, & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 362/ H.R. 733)
The Recalcitrant Cancer Research Act
Cancer patients needs in the essential health benefits package of the Affordable Care Act
Draft guidance on laboratory-developed tests
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The National Defense Authorization Act - Title X , Subtitle H, Section 1083 - Scientific framework for recalcitrant cancers
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 19, 2012.
Original Filing: 300513467.xml
Lobbying Issues
The Recalcitrant Cancer Research Act (formerly the Pancreatic Cancer Research & Education Act) (S. 362/H.R. 733)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
July 12, 2012 letter urging Congress to take a balanced approach to deficit reduction that does not include further cuts to nondefense discretionary (NDD) programs - signature of support.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300493308.xml
Lobbying Issues
Funding for cancer research in the FY 2013 Labor, Health, & Human Services Appropriations bill
Funding for the Peer-reviewed Cancer Research Program in the FY 2013 Department of Defense bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Pancreatic Cancer Research & Education Act (S. 362/ H.R. 733)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 19, 2012.
Original Filing: 300468159.xml
Lobbying Issues
Funding for cancer research in the FY 2013 Labor, Health, & Human Services Appropriations bill
Funding for the Peer-reviewed Cancer Research Program in the FY 2013 Department of Defense bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Cancer patients needs in the essential health benefits under the Affordable Care Act
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2011
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 19, 2012.
Original Filing: 300443741.xml
Lobbying Issues
Funding for cancer research in the FY 2012 Labor, Health, & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Draft Guidance for Industry and Food and Drug Administration Staff In Vitro Companion Diagnostic Devices
Cancer patients needs in the essential health benefits under the Affordable Care Act
Agencies Lobbied
Food & Drug Administration (FDA)
3rd Quarter, 2011
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 18, 2011.
Original Filing: 300417432.xml
Lobbying Issues
Funding for cancer research in teh FY 2012 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 362/ HR 733)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 19, 2011.
Original Filing: 300396417.xml
Lobbying Issues
Funding for cancer research in the FY 2012 Labor, Health & Human Services Appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 362/H.R. 733)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300376562.xml
Lobbying Issues
Funding for cancer research in the FY 2011 & FY 2012 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S.362/H.R. 733)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 19, 2011.
Original Filing: 300345452.xml
Lobbying Issues
Funding for cancer research in the FY 2011 Labor, Health & Human Services Appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 3320/H.R. 745)
The 21st Century ALERT Act (S. 717)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 19, 2010.
Original Filing: 300318039.xml
Lobbying Issues
Funding for cancer research in the FY 2011 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 3320/H.R. 745)
The 21st Century ALERT Act (S.717)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 21, 2010.
Original Filing: 300304192.xml
Lobbying Issues
Funding for cancer research in the FY 2010 & FY 2011 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (S. 3320/H.R. 745)
The 21st Century ALERT Act (S. 717)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 19, 2010.
Original Filing: 300265899.xml
Lobbying Issues
Funding for cancer research in the FY 2010 & FY 2011 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (H.R. 745)
The 21st Century ALERT Act (S. 717)
Health Care Reform (H.R. 3590), Sections 6301 & 6302 on comparative effectiveness research and Section 2709 on clinical trials
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300243032.xml
Lobbying Issues
Funding for cancer research in the FY 2010 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (H.R. 745)
The 21st Century ALERT Act (S. 717)
Health Care Reform (H.R. 3590), Sections 6301 & 6302 on comparative effectiveness research and Section 2709 on clincial trials
Comprehensive Cancer Care Improvement Act (H.R. 1844/S.1773)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Physician Fee Schedule for CY 2010
Proposed rule related to changes in Medicare Advantage and the Medicare Part D prescription drug program
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2009
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300218748.xml
Lobbying Issues
Funding for pancreatic cancer research in the FY 2010 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (H.R. 745)
The 21st Century Cancer ALERT Act (S.717)
Comprehensive Cancer Care Improvement Act (H.R. 1844)
Health Care Reform (no specific bill)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Physician Fee Schedule for CY 2010
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2009
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 19, 2009.
Original Filing: 300185807.xml
Lobbying Issues
Funding for pancreatic cancer research in the FY 2010 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (H.R. 745)
The 21st Century Cancer ALERT Act (S. 717)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 20, 2009.
Original Filing: 300163418.xml
Lobbying Issues
American Recovery and Reinvestment Act of 2009 (H.R. 1), increasing funding for NIH and NCI
Funding for pancreatic cancer research in the FY 2010 Labor, Health & Human Services Appropriations bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Pancreatic Cancer Research & Education Act (H.R. 745)
The 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act (S.717)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Jan. 16, 2009.
Original Filing: 300122593.xml
Lobbying Issues
Economic Stimulus Act of 2008 (H.R. 5140), increasing funding for NIH & NCI
S.3230, L-HHS Appropriations Act for FY2009, Title II, all provisions relating to the National Cancer Institute
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.Res.1328/S.Res. 720, "Supporting the goals and ideals of National Pancreatic Cancer Awareness Month"
H.R. 6791, "National Cancer Fund Act"
H.R. 7045, "National Plan to Advance Pancreatic Cancer Act"
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on Oct. 20, 2008.
Original Filing: 300108679.xml
Lobbying Issues
S.3230, L-HHS Appropriations Act for FY2009, Title II, all provisions relating to the National Cancer Institute
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Research, Condition, and Disease Categorization (RCDC) system
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.Res. 1328, "Supporting the goals and ideals of National Pancreatic Cancer Awareness Month"
H.R. 6791, "National Cancer Fund Act"
H.R. 7045, "National Plan to Advance Pancreatic Cancer Act"
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300082743.xml
Lobbying Issues
S.3230, L-HHS Appropriations Act for FY2009, Title II, all provisions relating to the National Cancer Institute
H.R.2642, FY2008 Supplemental Funding, provisions relating to the National Cancer Institute
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Research, Condition, and Disease Categorization (RCDC) system
NIH Peer Review
Agencies Lobbied
Natl Institutes of Health (NIH)
Lobbying Issues
H.R.2676/S.2999 - Access to Cancer Clinical Trials Act
H.R. 493/S.358 - Genetic Information Nondiscrimination Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare coverage for Positron Emission Tomography
Medicare coverage for Clinical Trials
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2008
In Q1, PANCREATIC CANCER ACTION NETWORK (PANCAN) had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300055448.xml
Lobbying Issues
Federal funding for pancreatic cancer research
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2006
Pancreatic Cancer Action Network (PanCAN) filed a lobbying registration on Sept. 5, 2006 for in-house lobbying efforts, effective July 10, 2006.
Original Filing: 100050342.xml
Issue(s) they said they’d lobby about: H.Res 745, Supporting the goals and ideals of Pancreatic Cancer Awareness Month
H.R. 5647, Labor-HHS Appropriations Act of 2006, Title 2, all provisions related to NCI and pancreatic cancer research.
S.3708, Labor-HHS Appropriations Act of 2006, Title 2, all provisions related to NCI and pancreatic cancer research .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...